Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexual Desire Disorder Clear all
Completed Not applicable Interventional

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

NCT03479229
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Geneveve Treatment, Sham Treatment
Device
Lead sponsor
Viveve Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

NCT01857596
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
bupropion, Lorexys low-dose, Lorexys moderate-dose
Drug
Lead sponsor
S1 Biopharma, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beachwood, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00338312
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00996164
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Zestra in Women With Mixed Sexual Dysfunction

NCT00118495
View directory record Official record
Conditions
Sexual Dysfunction, Psychological
Interventions
Non-prescription Zestra(TM): patented formulation
Drug
Lead sponsor
QualiLife Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2007 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation to Identify if Dame Product's "DLM" Works to Improve Sexual Desire and Mood in Females

NCT05130411
View directory record Official record
Conditions
Sexual Desire Disorder
Interventions
DLM - Test product
Dietary Supplement
Lead sponsor
Dame Products, Inc.
Industry
Eligibility
24 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Improving Female Sexual Wellness

NCT04824820
View directory record Official record
Conditions
Sexuality, Sexual Dysfunction, Sexual Desire Disorder, Hypoactive Sexual Desire Disorder, Orgasmic Disorder, Pelvic Organ Prolapse, Urinary Incontinence, Interstitial Cystitis, Pelvic Floor Disorders, Female Sexual Dysfunction
Interventions
Vibrator
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT02859285
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo vulvar cream, Estradiol vulvar cream
Other
Lead sponsor
ProHealth Care, Inc
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
transdermal testosterone gel 1%, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 66 Years · Female only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
98
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 22, 2026, 8:14 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

A Mindfulness-based Intervention for Older Women With Low Sexual Desire

NCT03232801
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
Interventions
mindfulness-based multicomponent intervention, general health education group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Acupuncture for Sexual Dysfunction

NCT02070029
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
Interventions
Acupuncture
Procedure
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

WISH, Feasibility of a Factorial Design

NCT07023822
View directory record Official record
Conditions
Breast Cancer, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder, Body Image
Interventions
Hyaluronic acid (HLA) Vaginal Moisturizer, Polycarbophil Vaginal Moisturizer, Hypnotic Relaxation, Progressive Muscle Relaxation (PMR)
Device · Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Surface Stimulation for Female Sexual Dysfunction

NCT02692417
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Timothy Bruns
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin, flibanserin 50mg, flibanserin 100mg, placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

NCT00467259
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
115
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT03287232
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
63
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

NCT01188603
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin 100 mg dose every evening
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Wichita, Kansas • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 22, 2026, 8:14 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

NCT01057901
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
35 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
84
States / cities
Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

NCT01040208
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Depression
Interventions
flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
42
States / cities
Costa Mesa, California • Fresno, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 22, 2026, 8:14 PM EDT